Global Human Papillomavirus Infection Drugs Market, By Diseases (Cervical Cancer, Anal Cancer, Genital Warts, Others), Drugs (Immunomodulators, Keratolytics, Antineoplastics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Human Papillomavirus Infection Drugs Market Analysis and Size
The global human papillomavirus infection drugs market is expected to witness significant growth during the forecast period. In the past few decades, there have been outstanding advances in the the natural history of human papillomavirus (HPV) infection and that its role as the main risk factor in the development of cervical and other anogenital cancers, which eventually has led to increased research and development in the human papillomavirus drug segment. The HPV vaccines are considered to be the most advanced types of therapeutics because of their ability to provide long term protection from the virus. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global human papillomavirus infection drugs market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Human papillomavirus (HPV) is a viral pathogen which is different from HIV. This HPV infection causes sexually transmitted infection. It is also a major cause of vulva, vagina, cervical, penis, mouth, and throat cancer. There are more than 100 types of HPV, and over 40 types of which have been transmitted through sexual activity and can affect your genital area, mouth, or neck.
Human Papillomavirus Infection Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diseases (Cervical Cancer, Anal Cancer, Genital Warts, Others), Drugs (Immunomodulators, Keratolytics, Antineoplastics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Cipla Inc. (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Nielsen Biosciences (U.S.), AIM ImmunoTech Inc (U.S.), Aclaris Therapeutics, Inc (U.S.)
|
|
Market Opportunities
|
|
Global Human Papillomavirus Infection Drugs Market Dynamics
Drivers
- Increased Cases of STI
The increasing prevalence of sexually transmitted infections (STIs) is expected to boost the market's growth. Around 38.4 million people were living with STI at the end of 2021 globally.
- Rising Incidence of Cervical Cancer
The number of cervical cancer rates are high in many underdeveloped countries, where more than 80% of cervical cancer cases are diagnosed. According to the WHO, cervical cancer is the most common type of malignancy in women and the second leading cause of cancer-related death globally, responsible for over 300,000 fatalities per year. This boosts the market gowth.
Opportunities
- Increasing Approvals For Vaccine
The rising approvals for vaccines is expected to expand the human papillomavirus (HPV) infection drugs market growth. For instance, in October 2018, the U.S FDA approved Gardasil 9, which is developed by Merck & Co., Inc. Gardasil 9 is developed for the treatment of cervical, vulvar, vaginal, and anal cancers caused by HPV types. This creates more opportunity to the market.
- Increasing Demand for Retail Pharmacies
The rise in cervical cancer led to the delivery of drugs through retail pharmacies, creating a surge in the number of retail pharmacies in developed countries. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat these HPV patients with appropriate treatments could curb the growth of the global human papillomavirus infection drugs market over a forecast period.
- High Cost
The huge expenditure associated with human papillomavirus infection drugs surely hamper the market growth.
This global human papillomavirus infection drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global human papillomavirus infection drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Human Papillomavirus Infection Drugs Market
COVID-19 pandemic has benefited the global human papillomavirus infection drugs market positively. Even though there was lockdown and many of the tasks were in consideration with COVID-19, most healthcare workers are carrying out their tasks, and companies are spending greatly in vaccine development for HPV.
The bigger population demand for HPV vaccine is likely to boost the market during a pandemic. Vaccine manufacturers and other scientists are working continuously on the development of HPV vaccines as well as COVID viral symptoms, which is predicted to boost the market in the next years.
Global Human Papillomavirus Infection Drugs Market Scope
The global human papillomavirus infection drugs market is segmented on the basis of diseases, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diseases
- Cervical Cancer
- Anal Cancer
- Genital Warts
- Others
Drugs
- Immunomodulators
- Keratolytics
- Antineoplastics
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Human Papillomavirus Infection Drugs Market Regional Analysis/Insights
The global human papillomavirus infection drugs market is analysed and market size insights and trends are provided by diseases, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global human papillomavirus infection drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global human papillomavirus infection drugs market throughout the forecasted period due to the large availability of treatment options and presence of sophisticated healthcare infrastructure which can results in effective treatment to patient suffering from the infectious.
Asia-Pacific dominates the market due to surge population and increase in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Human Papillomavirus Infection Drugs Market Share Analysis
The global human papillomavirus infection drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global human papillomavirus infection drugs market.
Key players operating in the global human papillomavirus infection drugs market include:
- Cipla Inc. (India)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc (U.K.)
- Nielsen Biosciences (U.S.)
- AIM ImmunoTech Inc (U.S.)
- Aclaris Therapeutics, Inc (U.S.)
SKU-